Channel Therapeutics Corporation
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a CHRO research report →
Price Chart
About the company
Channel Therapeutics Corporation operates as a clinical-stage biotechnology company, committed to the entire process of identifying, advancing, and bringing to market novel therapies aimed at reducing pain. Its research strategy centers on precisely inhibiting the NaV1. 7 sodium ion-channel, in addition to other related receptors within the broader NaV family.
- CEO
- Francis Knuettel II,
- IPO
- 2024
- Employees
- 4
- HQ
- Freehold, NJ, US
Get TickerSpark's AI analysis on CHRO
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $8.90M
- P/E
- -0.34
- PEG
- -0.01
- P/S
- 0.49
- P/B
- -3.98
- EV/EBITDA
- -1.40
- Div Yield
- 0.00%
- Gross Margin
- 68.23%
- Op Margin
- -101.59%
- Net Margin
- -123.24%
- ROE
- -381.40%
- ROIC
- -47.91%
Latest fiscal year · YoY change
- Revenue
- $16.80M+0.0%
- Gross Profit
- $0+0.0%
- Op Income
- $0
- Net Income
- $-43,319,000-444.5%
- EPS
- $-23.04-1511.2%
- OCF Growth
- -290.0%
- FCF Growth
- -291.7%
- 52W High
- $54.29
- 52W Low
- $1.23
- 50D MA
- $12.03
- 200D MA
- $12.00
- Beta
- 3.29
- RSI (14)
- 58
- Avg Volume
- 111.31K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Pelthos posted another strong Zelsuvmi quarter with 114% year-over-year revenue growth, while also outlining plans to expand with Xepi, Xeglyze, and the announced Castle Creek transaction.· November 12, 2026
- Zelsuvmi Q3 net revenue was $15.2 million, up 114% year over year, with 12,384 prescriptions, up 365% year over year.
- Formulary access improved meaningfully: a major PBM contract added about 24 million covered lives without prior authorization, and total commercial coverage reached 127 million lives.
- Gross-to-net was 31.5% in Q3 and management expects it to move into the mid-30s range as additional formulary coverage comes in.
- The company continues to ramp Xepi and Xeglyze, with Xepi expected to be promoted by the end of Q1 2027 and Xeglyze expected to launch by the end of Q3 2027.
- Management framed the Castle Creek deal as a strategic pivot toward a more diversified biotech model, centered on D-Fi in rare disease.
Pelthos reported Q3 2026 net product revenue of $15.2 million, versus $15.4 million in Q2 2026, and said this was up 114% year over year from Q3 2025. Gross-to-net was 31.5% in Q3 2026 versus 29.6% in Q2 2026; cost of goods sold was $1.7 million versus $3.6 million; SG&A was $18.8 million versus $25.0 million; net loss was $7.9 million versus $23.4 million; and adjusted EBITDA was negative $5.6 million versus negative $5.7 million. Since Zelsuvmi’s launch, Pelthos said it has generated $57.5 million of net product revenue across five fiscal quarters, dispensed over 40,000 units, and treated over 31,000 patients. On the balance sheet, cash was $17.7 million and accounts receivable were $13.4 million at September 30, 2026. For forward commentary, management said Zelsuvmi GTN should move into the mid-30s range, Xepi promotion should begin by the end of Q1 2027, and Xeglyze should launch by the end of Q3 2027. The company also said it drew an additional $10 million from its Horizon term loan on October 30, with a further $10 million potentially available before December 31, 2027, subject to conditions including trailing 12-month net revenue of at least $70 million.
Scott Plesha said Q3 was successful operationally and emphasized that Zelsuvmi’s formulary gains should support future growth, even though the PBM deal pushed gross-to-net higher in the near term. He highlighted the strategic importance of building a broader dermatology platform, including Xepi and Xeglyze, and described the Castle Creek acquisition as a way to expand Pelthos into a more diversified biotech company with a late-stage rare-disease asset. His tone was upbeat and expansionary, but he repeatedly noted that the company is in a quiet period on the transaction and cannot say much more until the S-4 is filed.
John Gay focused on the quarter’s financial mechanics and balance-sheet flexibility. He said Q3 net product revenue was $15.2 million, gross-to-net was 31.5%, COGS fell to $1.7 million, SG&A declined to $18.8 million, net loss improved to $7.9 million, and adjusted EBITDA was negative $5.6 million. He also walked through inventory accounting, saying the company expects to consume the remaining stepped-up ATI inventory within 12 to 15 months and then expects normalized per-unit cost of goods to be approximately a mid- to high single digit of WAC price. On liquidity, he said Pelthos had $17.7 million of cash, had already drawn $30 million from the Horizon facility plus an additional $10 million on October 30, and believes it has the flexibility to advance the business plan.
Analysts focused on Zelsuvmi growth durability, gross-to-net direction, Xepi’s payer landscape, and the Castle Creek deal. Management said the GTN increase was a deliberate long-term investment to unlock a major PBM and remove prior authorization, and that it could have delivered modestly higher quarter-over-quarter revenue without that decision. On Xepi, they said payer conversations are going well and that resistance to mupirocin/Naprosyn is part of the market need they are seeing. On Castle Creek, management declined to go deep on D-Fi versus VYJUVEK or other comparables because of the quiet period, but said early diligence and KOL feedback gave them confidence the asset fits well in DEB and may be used first line and/or in combination. They also said the current field force can support the launches, though they may add a handful of reps if the economics justify it.
The bull case from this call is that Zelsuvmi continues to gain adoption, with more than 10,000 unique prescribers, improving access, and a second-highest monthly performance in October after Q3. Management sounded confident that the formulary wins will take time to work through the system and should support growth into 2027, while Xepi and Xeglyze could add operating leverage by using the same field force. The Castle Creek deal adds a late-stage rare-disease asset and broadens the company beyond a single-product story.
The main risks discussed were near-term gross-to-net pressure, seasonal variability in molluscum prescriptions, and the fact that the Castle Creek transaction is still subject to regulatory and closing steps. Management acknowledged that Q3 revenue was slightly below Q2 and that some of the formulary benefit has not yet shown up fully in results. The deal also brings dilution and execution risk, since D-Fi still needs to complete Phase III and Pelthos remains limited in what it can say until the S-4 is filed.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 38.8%
- Shares Outstanding
- 6.60M
- Float Shares
- 2.56M
of shares held by institutions
9 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Apr 11, 25 | Simmons Chia-Lin | other | 25,000 |
| Apr 11, 25 | Francis Knuettel II | other | 53,988 |
| Nov 13, 24 | Davis Todd C | other | 49,605 |
| Nov 13, 24 | Malamut Richard | other | 24,533 |
| Nov 13, 24 | Friedberg Ezra M | other | 24,533 |
| Sep 12, 24 | Malamut Richard | buy | 10,400 |
| Sep 13, 24 | Francis Knuettel II | buy | 3,500 |
| Sep 12, 24 | Francis Knuettel II | buy | 1,700 |
| Sep 11, 24 | Francis Knuettel II | buy | 5,500 |
| Sep 10, 24 | Francis Knuettel II | buy | 6,500 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our CHRO coverage
Recent articles, reports, and earnings notes.
No research on CHRO yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate CHRO report →WTW's Kristy Banas Recognized with the 2026 N2Growth Leaders40 Top CHRO Award
globenewswire.com · Nov 16
New IBM CHRO Study: AI Puts Critical Thinking at the Center of Workforce Priorities
gurufocus.com · Sep 21
Five Below CHRO Maureen Gellerman Sells 1,610 Shares for $401,000
fool.com · Sep 17
Channel Therapeutics Announces Reverse Common Stock Split in Conjunction with the Close of the Merger with Pelthos Therapeutics and Concurrent $50.1 Million Private Placement
globenewswire.com · Jun 27
Channel Therapeutics Provides Announcement on 2024 Annual Report to Comply with NYSE American Listing Rules
globenewswire.com · May 1
Channel Therapeutics Highlights Differences Between NaV1.7 and NaV1.8 in Light of Recent Clinical Data on Suzetrigine
globenewswire.com · Dec 20
Channel Therapeutics Announces Positive Efficacy Data For a Depot Formulation of a NaV1.7 Inhibitor in a Preclinical In Vivo Nerve Block Model
globenewswire.com · Dec 18
Chromocell Announces Name Change to “Channel Therapeutics Corporation” and Provides Therapeutic Program Updates
globenewswire.com · Nov 21
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.